Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P250023/S001

Allurion Gastric Balloon System

Allurion Technologies, Inc. · Decision date Sep 9, 2026

FDA DECISIONP250023/S001

What did the FDA approve?

FDA records P250023/S001 as a supplement to PMA P250023, with the supplement type “Special (Immediate Track)”. The recorded decision is approval, dated Sep 9, 2026.

FDA approval order statement

revisions to the patient labeling, physician labeling and patient information card to enhance product safety information
Regulatory pathway
PMA supplement
Supplement type
Special (Immediate Track)
Clinical specialty
Gastroenterology, Urology
Decision date
Sep 9, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P250023/S001
Regulatory pathway
PMA supplement
Product code
LTI
Decision code
APPR
Decision date
Sep 9, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: IMPLANT, INTRAGASTRIC FOR MORBID OBESITY.

Product code
LTI
FDA device class
3

For the original device and its historical approval scope, see PMA P250023. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P250023 · Original PMA

    Allurion Gastric Balloon System

  2. P250023/S001 received

    Application receipt date recorded by FDA.

  3. P250023/S001 · FDA decision

    Special (Immediate Track)

  4. P250023/S002 · Related supplement

    Allurion Gastric Balloon System

Timeline entries are records held by MedtechLedger for P250023. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250023

Product / regulatory recordCompanyPathwayDecision dateSource
Allurion Technologies, Inc.PMA approvalFeb 20, 2026FDA
Allurion Technologies, Inc.PMA supplementSep 23, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Allurion Technologies, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
11 Huron Dr., Natick, MA, 01760

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records